Evidence map›Paper›PMID 36230970›Full record

ArticleCells2022

m

Yibo Bian, Yang Wang, Shufen Xu, Zhishuang Gao, Chao Li, Zongyao Fan, Jie Ding, Keming Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. NNature reviews. Cancer · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Progression of mCell death discovery · 2024
    Review
  13. Article
  14. Review
  15. Non-coding RNA-Mediated N6-Methyladenosine (mNon-coding RNA research · 2024
    Review
  16. Review
  17. Review
  18. New insights into the regulation of METTL3 and its role in tumors.Cell communication and signaling : CCS · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yibo BianDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Yang WangDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Shufen XuDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zhishuang GaoDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Chao LiDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zongyao FanDepartment of Urology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jie DingDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Keming WangDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Second Affiliated Hospital of Nanjing Medical University · CNJiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNAs modulate tumor occurrence through different molecular mechanisms. It had been reported that HNF1A-AS1 (HNF1A Antisense RNA 1) was differently expressed in multiple tumors. The role of HNF1A-AS1 in colorectal cancer was less analyzed, and the mechanism of regulating the cell cycle has not been completely elucidated.

methodsDifferentially expressed lncRNAs were screened out from the TCGA database. HNF1A-AS1 was examined in CRC clinical samples and cell lines by RT-qPCR. CCK8 assay, colony formation assay, flow cytometry, transwell assays, tube forming assay and vivo experiments were performed to study the function of HNF1A-AS1 in CRC tumor progression. Bioinformatic analysis, luciferase report assay, RNA pull-down and RIP assays were carried out to explore proteins binding HNF1A-AS1 and the potential downstream targets.

resultsOur results showed that HNF1A-AS1 was upregulated in CRC and associated with unfavorable prognosis. HNF1A-AS1 promoted proliferation, migration and angiogenesis, accelerated cell cycle and reduced cell apoptosis in CRC. Bioinformatics prediction and further experiments proved that HNF1A-AS1 could promote CCND1 expression by suppressing PDCD4 or competitively sponging miR-93-5p. Meanwhile, METTL3 mediated HNF1A-AS1 m

conclusionIn summary, our result reveals the novel mechanism in which m

Indexed as

Colorectal NeoplasmsMicroRNAsRNA, Long NoncodingApoptosis Regulatory ProteinsCell CycleCell Line, TumorCell MovementCell ProliferationCyclin D1Gene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 1-alphaHumansMethyltransferasesRNA-Binding ProteinsRNA, MessengerApoptosis Regulatory ProteinsCCND1 protein, humanCyclin D1Hepatocyte Nuclear Factor 1-alphaHNF1A protein, humanIGF2BP2 protein, humanMethyltransferasesMETTL3 protein, humanMicroRNAsPDCD4 protein, humanRNA-Binding ProteinsRNA, Long NoncodingRNA, MessengerCCND1colorectal cancerHNF1A-AS1IGF2BP2m6A

Identifiers

PMID36230970
PMCPMC9562639
OpenAlexW4297348585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.